Literature DB >> 25965716

Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography.

Ahmad Masri1, Lee M Pierson1, Nicholas G Smedira1, Shikhar Agarwal1, Bruce W Lytle1, Peyman Naji1, Maran Thamilarasan1, Harry M Lever1, Leslie S Cho1, Milind Y Desai2.   

Abstract

BACKGROUND: Patients with hypertrophic cardiomyopathy (HCM) have exercise intolerance due to left ventricular outflow tract (LVOT) obstruction, mitral regurgitation, and left ventricular dysfunction. We sought to study predictors of outcomes in HCM patients undergoing cardiopulmonary stress testing (CPT).
METHODS: We studied 1,005 HCM patients (50 ± 14 years, 64% men, 77% on β-blockers) who underwent CPT with echocardiography. Clinical, echocardiographic, and exercise variables (peak oxygen consumption [VO2] and heart rate recovery [HRR] at first minute postexercise) were recorded. End point was a composite of death, appropriate defibrillator discharges, resuscitated sudden death, stroke, and heart failure admission.
RESULTS: Mean left ventricular ejection fraction (LVEF), postexercise LVOT gradient, and peak VO2 were 62% ± 6%, 92 ± 51 mm Hg, and 21 ± 6 mL kg(-1) min(-1), respectively. Despite 789 patients (78%) being in New York Heart Association classes I to II, only 8% achieved >100% age-gender predicted peak VO2, whereas 77% and 15% achieved 50% to 100% and <50%, respectively. Left ventricular outflow tract gradient ≥30 mm Hg was observed in 83% patients, whereas 23% had abnormal HRR. More than 5.5 ± 4 years, there were 94 (9%) events; 511 (50%) patients underwent surgery for LVOT obstruction. Multivariable Cox proportional analysis demonstrated % age-gender predicted peak VO2 (hazard ratio [HR] 0.96 [0.93-0.98]), normal vs abnormal HRR (HR 0.48 [0.32-0.73]), higher LVEF (HR 0.96 [0.93-0.98]), surgery (0.53 [0.33-0.83]), and atrial fibrillation (HR 1.65 [1.04-2.60]) were associated with outcomes (all P < .05).
CONCLUSIONS: In HCM patients undergoing CPT, a higher % of achieved age-gender predicted VO2 and surgical relief of LVOT obstruction were associated with better outcomes, whereas abnormal HRR, atrial fibrillation, and lower LVEF were associated with worse outcomes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25965716     DOI: 10.1016/j.ahj.2015.02.006

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  Commentaries on Viewpoint: V̇o2peak is an acceptable estimate of cardiorespiratory fitness but not V̇o2max.

Authors:  Paulo Azevedo; Dharini M. Bhammar; Tony G. Babb; T. Scott Bowen; Klaus K. Witte; Harry B. Rossiter; Julien V. Brugniaux; Ben D. Perry; Ricardo Dantas de Lucas; Tiago Turnes; Jeann L. Sabino-Carvalho; Thiago Ribeiro Lopes; Rodrigo Zacca; Ricardo J. Fernandes; Greg L. McKie; Tom J. Hazell; Lucas Helal; Anderson Donelli da Silveira; Craig Ryan McNulty; Robert Andrew Roberg; Tom E. Nightingale; Abdullah A. Alrashidi; Evgeny Mashkovskiy; Andrei Krassioukov; Pierre Clos; Davy Laroche; Benjamin Pageaux; David C. Poole; Andrew M. Jones; Gustavo Z. Schaun; Diego Santos de Souza; Tatiane de Oliveira Barreto Lopes; Mary Vagula; Li Zuo; Tingyang Zhao
Journal:  J Appl Physiol (1985)       Date:  2018-07-01

Review 2.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 3.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

4.  Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis.

Authors:  Ahmad Masri; Mohamed Kanj; Maran Thamilarasan; Oussama Wazni; Nicholas G Smedira; Harry M Lever; Milind Y Desai
Journal:  Cardiovasc Diagn Ther       Date:  2017-02

Review 5.  Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.

Authors:  Tiffany T S Ye; Qi Zhuang Siah; Benjamin Y Q Tan; Jamie S Y Ho; Nicholas L X Syn; Yao Hao Teo; Yao Neng Teo; James W Yip; Tiong-Cheng Yeo; Weiqin Lin; Raymond C C Wong; Ping Chai; Bernard Chan; Vijay Kumar Sharma; Leonard L L Yeo; Ching-Hui Sia
Journal:  J Thromb Thrombolysis       Date:  2022-10-03       Impact factor: 5.221

Review 6.  Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.

Authors:  Ariane Fraiche; Andrew Wang
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

7.  Assessment of Exercise Function in Children and Young Adults with Hypertrophic Cardiomyopathy and Correlation with Transthoracic Echocardiographic Parameters.

Authors:  Robert Przybylski; Ilana R Fischer; Kimberlee Gauvreau; Mark E Alexander; Keri M Shafer; Steven D Colan; Christa Miliaresis; Jonathan Rhodes
Journal:  Pediatr Cardiol       Date:  2022-01-20       Impact factor: 1.655

Review 8.  Heart transplantation in patients with hypertrophic cardiomyopathy.

Authors:  Marta Farrero Torres; Felix Perez-Villa
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

Review 9.  Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Adrián Bayonas-Ruiz; Francisca M Muñoz-Franco; Vicente Ferrer; Carlos Pérez-Caballero; María Sabater-Molina; María Teresa Tomé-Esteban; Bárbara Bonacasa
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

10.  Predictors of Exercise Capacity in Patients with Hypertrophic Obstructive Cardiomyopathy.

Authors:  Joshua R Smith; Jose R Medina-Inojosa; Veronica Layrisse; Steve R Ommen; Thomas P Olson
Journal:  J Clin Med       Date:  2018-11-18       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.